REGISTER
Five Sustained- and Controlled-Release Neurology Drugs: Risks of Splitting or Crushing
Crushing or splitting sustained- and controlled-release tablets can cause dose dumping. A reported case involved a patient receiving crushed extended-release nifedipine and labetalol via nasogastric tube who died after cardiac arrest. This review covers five neurology sustained-release drug classes that must never be split or crushed: valproate, carbidopa-levodopa, venlafaxine, nifedipine, and piribedil. Risks include hypotension, arrhythmias, and serotonin syndrome.

Case Introduction

A 38-year-old woman with comorbid hypertension, end-stage renal disease, HIV, and asthma was admitted with acute pulmonary edema and pneumonia. Her condition was critical and required endotracheal intubation. After clinical stabilization, oral hydralazine, labetalol, and extended-release nifedipine were prescribed. Because the patient was unable to swallow independently, a nurse crushed all medications and administered them via nasogastric tube.

Shortly after administration, the patient developed progressive bradycardia and severe hypotension, progressing to cardiac arrest. Resuscitation transiently restored circulation. The following day, the same doses of labetalol and extended-release nifedipine were again crushed and administered via the nasogastric tube. The patient developed recurrent junctional bradycardia, shock, and repeated cardiac arrest. Despite treatment with calcium, glucagon, and high-dose vasopressors, resuscitation failed and the patient was declared dead.

Such events are not isolated. Among neurology outpatients and inpatients, many patients—seeking convenience, attempting dose adjustment, or coping with dysphagia—habitually split, crush, or chew their tablets. A common misconception is that altering a tablet’s physical form does not affect its efficacy. In reality, this seemingly minor convenience carries substantial medication-safety risks.

I. Why Sustained- or Controlled-Release Formulations Must Not Be Split

Think of sustained- or controlled-release formulations as precision-engineered drug delivery systems. These products rely on specialized coatings, drug matrices, or osmotic-pump designs to release medication in a controlled, gradual, and continuous fashion. Compared with standard immediate-release tablets, modified-release products offer several advantages [1-2]:

  • l Stable plasma concentrations: drug effects remain consistent rather than fluctuating, providing more stable control of chronic and neurologic conditions.
  • l Simpler, longer-acting dosing: extended duration reduces daily dosing frequency and improves adherence.
  • l Lower toxicity: avoiding the abrupt release of a large bolus minimizes overdose risk.

Crushing, splitting, or chewing such tablets destroys the controlled-release structure. A dose designed for gradual release over 12-24 hours may instead be absorbed within tens of minutes, causing plasma levels to spike and potentially triggering severe toxicity or organ damage.

II. Five Modified-Release Neurology Drugs That Must Never Be Split or Crushed

1. Antiepileptic: Sodium valproate sustained-release tablets

Sodium valproate sustained-release tablets are commonly used in epilepsy treatment. The tablet uses a homogeneous matrix sustained-release structure. When swallowed intact, the drug is released steadily, maintaining stable plasma concentrations and effectively controlling seizures.

The prescribing label specifies that the tablet should be swallowed whole; it may be halved but must not be crushed or chewed.

If the tablet is split or crushed, the sustained-release barrier fails completely, causing the drug to be rapidly and massively absorbed. Plasma concentrations may spike, triggering dizziness, somnolence, and limb ataxia; in severe cases, seizure frequency may paradoxically increase.

2. Anti-Parkinson: Carbidopa-levodopa sustained-release tablets

Parkinson’s patients have low tolerance for plasma fluctuations: small shifts in levodopa concentration can cause marked symptoms. The sustained-release formulation is designed to provide stable drug delivery and continuous relief of rigidity, tremor, and bradykinesia.

The prescribing label states that the tablet may be taken whole or as a half tablet; this preserves the sustained-release properties. Tablets must not be chewed or crushed.

Once split open, the drug surges into the bloodstream, potentially causing severe nausea, orthostatic hypotension, and—most seriously—worsening “on-off phenomenon,” in which patients swing between immobility and involuntary dyskinesia, with substantial physical suffering.

3. Antidepressant/anxiolytic: Venlafaxine extended-release capsules

Venlafaxine extended-release capsules are commonly used to treat depression and anxiety disorders. The internal pellets are coated to enable sustained release.

The prescribing label specifies that the capsule should be swallowed whole and must not be opened, crushed, chewed, or dissolved.

Opening the capsule or crushing its contents disrupts the sustained-release coating, allowing a large bolus of drug to be absorbed at once. This may trigger a sharp rise in blood pressure, arrhythmias, and—in severe cases—fatal serotonin syndrome, with agitation, persistent hyperthermia, and muscle rigidity, threatening life.

4. Cerebrovascular/hypertensive: Nifedipine controlled-release or sustained-release tablets

① Nifedipine controlled-release tablets

Nifedipine controlled-release tablets have laser-drilled release pores. If the outer controlled-release membrane is damaged, the entire drug load is released at once, briefly producing strong vasodilation and a sharp drop in blood pressure. This may precipitate severe headache, flushing, palpitations, orthostatic hypotension, and syncope. The controlled-release matrix itself is not absorbed and is excreted intact in stool—this is normal and should not cause alarm.

The prescribing label specifies that the tablet must be swallowed whole and must not be split, crushed, or chewed.

② Nifedipine sustained-release tablets

For most matrix-type sustained-release formulations: only a few scored tablets may be halved along the score line; crushing or chewing is forbidden. For unscored sustained-release tablets, treat as controlled-release and swallow whole.

Once chewed or crushed, the sustained-release structure collapses, plasma concentrations rise and fall sharply, and blood pressure fluctuates dramatically. Repeated inappropriate splitting substantially increases the long-term risk of myocardial infarction and stroke. Brief bolus-style dosing also frequently triggers tachycardia and worsening ankle edema.

5. Anti-Parkinson: Piribedil sustained-release tablets

Piribedil sustained-release tablets are mainly used to improve motor symptoms in Parkinson’s disease and likewise employ a sustained-release matrix. Continuous, steady release is achieved only by swallowing the tablet whole, providing sustained improvement of tremor and rigidity.

The drug must not be split, crushed, or chewed. Destruction of the sustained-release structure allows a massive bolus of drug to enter the bloodstream, triggering dizziness, nausea, blood pressure fluctuations, and psychiatric symptoms. Not only does this compromise therapeutic efficacy, it may worsen disease and provoke complications.

III. How to Determine if a Tablet Can Be Split

By name: products whose names include “sustained-release,” “controlled-release,” or “enteric-coated”are typically prohibited from being split, crushed, or chewed.

By appearance: without a central score line, modified-release products usually cannot be split. Even tablets with score lines should be confirmed against the prescribing label—only those explicitly labeled as scoreable may be divided.

By prescribing label: this is the most authoritative source. If the “Dosage and Administration” or “Precautions” section specifies “swallow whole” or “must not be crushed or chewed,”these instructions must be followed strictly.

IV. What About Swallowing Difficulties or Dose Adjustment?

Some patients split tablets because of dysphagia or a need to take half a dose. In these situations, do not self-manage. Instead:

  • l Consult a physician or pharmacist first to switch to an immediate-release formulation, oral solution, or granules.
  • l Patients requiring enteral feeding should not have modified-release preparations crushed; an immediate-release alternative should be used instead.
  • l Do not use knives, teeth, or devices to cut, chew, or crush tablets; never modify the dosage form on your own.

Summary

Modified-release neurology drugs must, in most cases, not be split or crushed arbitrarily. Disruption of the sustained-release structure may cause massive, instantaneous drug absorption, triggering severe blood pressure fluctuations, toxicity, symptom worsening, or even death. Whether a tablet can be divided depends on its name, score line, and prescribing label. Patients with dysphagia or those needing dose adjustment should always consult their care team for an appropriate formulation and never self-modify their medication.

References

[1] Schier JG, Howland MA, Hoffman RS, Nelson LS. Fatality from administration of labetalol and crushed extended-release nifedipine. Ann Pharmacother. 2003;37(10):1420-1423. doi:10.1345/aph.1D091

[2] Saran AK, Holden NA, Garrison SR. Concerns regarding tablet splitting: a systematic review. BJGP Open. 2022;6(3):BJGPO.2022.0001. Published 2022 Sep 28. doi:10.3399/BJGPO.2022.0001

0
0
Loading